Antimicrobial efficacy of doripenem and its combinations with sulbactam, amikacin, colistin, tigecycline in experimental sepsis of carbapenem-resistant Acinetobacter baumannii

New Microbiologica

Volumn 38, Issue 1, 2015, Pages 67-73

  Dinc, Gokcen ^a   Demiraslan, Hayati ^a   Elmali, Ferhan ^a   Ahmed, Salman Shaheer ^a   Alp, Emine ^a   Doganay, Mehmet ^a  

^a ERCIYES UNIVERSITY   (Turkey)

Author keywords

Acinetobacter baumannii; Antibiotic therapy; Experimental sepsis

Indexed keywords

ACINETOBACTER BAUMANNII; BACTERIA (MICROORGANISMS); MUS;

AMIKACIN; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; COLISTIN; DORIPENEM; MINOCYCLINE; SULBACTAM; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HUMAN; MALE; MICROBIOLOGY; MOUSE; MULTIDRUG RESISTANCE; SEPSIS;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; AMIKACIN; ANIMALS; ANTI-BACTERIAL AGENTS; CARBAPENEMS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MALE; MICE; MICE, INBRED BALB C; MINOCYCLINE; SEPSIS; SULBACTAM;

EID: 84923035916     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. ALP E., KALIN G., COSKUN R., SUNGUR M., GUVEN M., DOGANAY M. (2012). Economic burden of ventilator-associated pneumonia in a developing country. J. Hosp. Infect. 81, 128-130.
2. BERNABEU-WITTEL M., PICHARDO C., GARCÍA-CURIEL A., PACHÓN-IBÁÑEZ M.E., IBÁÑEZ-MARTINEZ J., JIMÉNEZ-MEJIAS M.E., PACHÓN J. (2005). Pharmacokinetic/ pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia. Clin. Microbiol. Infect. 11, 319-325.
3. BRETONNIÈRE C., JACQUELINE C., CAILLON J., GUITTON C., LE MABECQUE V., MIÉGEVILLE A.F., VILLERS D., POTEL G., BOUTOILLE D. (2010). Efficacy of doripenem in the treatment of Pseudomonas aeruginosa experimental pneumonia versus imipenem and meropenem. J. Antimicrob. Chemother. 65, 2423-2427.
4. CISNEROS J.M., REYES M.J., PACHÓN J., BECERRIL B., CABALLERO F.J., GARCÍA-GARMENDÍA J.L., ORTIZ C., COBACHO A.R. (1996). Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin. Infect. Dis. 22, 1026-1032.
5. CLSI. (2012). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard M07-A9,ed 9. Wayne, National Committee for Clinical Laboratory Standarts.
6. DEDHIA H.V., MCKNIGHT R. (2009). Doripenem: position in clinical practice. Expert. Rev. Anti Infect. Ther. 7, 507-514.
7. DEVECI A., COBAN A.Y., ACICBE O., TANYEL E., YAMAN G., DURUPINAR B. (2012). In vitro effects of sulbactam combinations with different antibiotic groups against clinical Acinetobacter baumannii isolates. J. Chemother. 24, 247-252.
8. DINC G., DEMIRASLAN H., ELMALI F., AHMED S.S., ALP E., DOGANAY M. (2013). Efficacy of sulbactam and its combinations with imipenem, colistin and tigecycline in experimental model of carbapenem resistant Acinetobacter baumannii sepsis. Chemotherapy. 59, 325-329.
9. ENTENZA J.M., MOREILLON P. (2009). Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies. Int. J. Antimicrob. Agents. 34, 8.e1-9. doi: 10.1016.
10. EUCAST. (2013). Break point tables for interpretation of MICs and zone diameters. The European Committee on Antimicrobial Susceptibility Testing Version 3.1.
11. FALAGAS M.E., KASIAKOU S.K. (2005). Colistin: The revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin. Infet. Dis. 40, 1333-1341.
12. GARZA-GONZÁLEZ E., LLACA-DÍAZ J.M., BOSQUES-PADILLA F.J., GONZÁLEZ G.M. (2010). Prevalence of multidrug-resistant bacteria at a tertiary-care teaching hospital in Mexico: special focus on Acinetobacter baumannii. Chemotherapy. 56, 275-279.
13. HOU P.F., CHEN X.Y., YAN G.F., WANG Y.P., YING C.M. (2012). Study of the correlation of imipenem resistance with efflux pumps AdeABC, AdeIJK, AdeDE and AbeM in clinical isolates of Acinetobacter baumannii. Chemotherapy. 58, 152-158.
14. HOUSMAN S.T., HAGIHARA M., NICOLAU D.P., KUTI J.L. (2013). In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii. J. Antimicrob. Chemother. 68, 2296-2304.
15. KALIN G., ALP E., AKIN A., COSKUN R., DOGANAY M. (2013). Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. Infection, DOI 10.1007/s15010-013-0495-y.
16. KEAM S.J. (2008). Doripenem: a review of its use in the treatment of bacterial infections. Drugs. 68, 2021-2057.
17. KEMPF M., DJOUHRI-BOUKTAB L., BRUNEL J., RAOULT D., ROLAIN J. (2012). Synergistic activity of sulbactam combined with colistin-resistant Acinetobacter baumannii. Int. J. Antimicrob. Agents. 39, 180-181.
18. KO W.C., LEE H.C., CHIANG S.R., YAN J.Y., WU J., LU C., CHUANG Y. (2004). In vitro and in vivo activity of meropenem and sulbactam against a multidrug-resistant Acinetobacter baumannii strain. J. Antimic. Chemother. 53, 393-395.
19. LAMBIASE A., PIAZZA O., ROSSANO F., DEL PEZZO M., TUFANO R., CATANIA M.R. (2012). Persistence of carbapenem-resistant Acinetobacter baumannii strains in an Italian intensive care unit during a forty-six month study period. New Microbiol. 35, 199-206.
20. LEMOS E.V., HOZ F.P., ALVIS N., EINARSON T.R., QUEVEDO E., CASTANEDA C., LEON Y., AMADO C., CANON O., KAWAI K. (2013). Impact of carbapenem resistance on clinical and economic outcomes among patients with Acinetobacter baumannii infection in Colombia. Clin. Microbiol. Infect. DOI: 10.1111/1469-0691.12251.
21. LLACA-DÍAZ J.M., MENDOZA-OLAZARÁN S., CAMACHO-ORTIZ A., F LORES S., GARZA GONZÁLEZ E. (2012). One-year surveillance of ESKAPE pathogens in an intensive care unit of Monterrey, Mexico. Chemotherapy. 58, 475-81.
22. MARTI S., SÁNCHEZ-CÉSPEDES J., ALBA V., VILA J. (2009). In vitro activity of doripenem against Acinetobacter baumannii clinical isolates. Int. J. Antimicrob. Agents. 33, 181-182.
23. MONTERO A., ARIZA J., CORBELLA X., DOMÉNECH A., CABELLOS C., AYATS J., TUBAU F., ARDANUY C., GUDIOL F. (2002). Efficacy of colistin versus β-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob. Agents. Chemother. 46, 1946-1952.
24. MONTERO A., ARIZA J., CORBELLA X., DOMENECH A., CABELLOS C., AYATS J., TUBAU F., BORRAZ C., GUDIOL F. (2004). Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J. Antimicrob. Chemother. 54, 1085-1091.
25. MOTAOUAKKIL S., CHARRA B., HACHIMI A., NEJMI H., BENSLAMA A., ELMDAGHRI N., BELABBESH., BENBACHIR M. (2006). Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J. Infect . 53, 274-278.
26. NOWAK P., PALUCHOWSKA P., BUDAK A. (2012). Distribution of blaOXA genes among carbapenem-resistant Acinetobacter baumannii nosocomial strains in Poland. New Microbiol. 35, 317-325.
27. OLIVEIRA M.S., PRADO G.V.B., COSTA S.F., GRINBAUM R.S., LEVIN A.S. (2008). Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J. Antimicrob. Chemother. 61, 1369-1375.
28. PACHÓN-IBÁÑEZ M.E, FERNANDEZ-CUENCA F., DOCOBO-PEREZ F., PACHÓN J., PASCUAL A. (2006). Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam. J. Antimicrob.Chemother. 58, 689-692.
29. PACHÓN-IBÁÑEZ M.E., DOCOBO-PÉREZ F., LÓPEZ-ROJAS R., DOMINGUEZ-HERRERA J., JIMÉNEZ-MEJIAS M.E., GARCIA-CURIEL A., PICHARDO C., JIMÉNEZ L., PACHÓN J. (2010). Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii. Antimicrob. Agents. Chemother. 54, 1165-1172.
30. PANTOPOULOU A., GIAMARELLOS-BOURBOULIS E.J., RAFTOGANNIS M., TSAGANOS T., DONTAS I., KOUTOUKAS P., BAZIAKA F., G IAMARELLOU H., PERREA D. (2007). Colistin offers prolonged survival in experimental infection by multidrug-resistant Acinetobacter baumannii: the significance of co-administration of rifampicin. Int. J. Antimicrob. Agents. 29, 51-55.
31. PEREZ F., HUJER A. M., HUJER K.M., DECKER B. K., RATHER P. N., BONOMO R. (2007). Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 51, 3471-3484.
32. POIREL L., N ORDMANN P. (2006). Carbapenem resistance in Acinetobacter baumannii : mechanisms and epidemiology. Clin. Microbiol. Infect. 12, 826-836.
33. PONGPECH P., AMORNOPPARATTANAKUL S., PANAPAKDEE S., FUNGWITHAYA S., NANHA P., DHIRAPUTRA C., LEELARRASAMEE A. (2010). Antibacterial activity of carbapenem-based combinations against multidrug-resistant Acinetobacter baumannii. J. Med. Assoc. Thai. 93, 161-171.
34. PRINCIPE L., CAPONE A., MAZZARELLI A., D'AREZZO S., BORDI E., DI CARO A., PETROSILLO N. (2013). In vitro activity of doripenem in combination with various antimicrobials against multidrug-resistant Acinetobacter baumannii: Possible options for the treatment of complicated infection. Microb. Drug. Resist. 19, 407-414.
35. QUEENAN A.M., DAVIES T.A., HE W., LYNCH A.S. (2013). Assessment of the combination of doripenem plus a fluoroquinolone against non-susceptible Acinetobacter baumannii isolates from nosocomial pneumonia patients. J. Chemother. 25, 141-147.
36. ROBERTS S.A., FINDLAY R., LANG S.D.R. (2001). Investigation of an outbreak of multi-drug resistant Acinetobacter baumannii in an intensive care burns unit. J. Hosp. Infect. 48, 228-232.
37. RODRÍGUEZ-HERNÁNDEZ M.J, CUBEROS L., PICHARDO C., CABALLERO F.J., MORENO I., JIMÉNEZ-MEJÍAS M.E., GARCÍA-CURIEL A., PACHÓN J. (2001). Sulbactam efficacy in experimental models caused by susceptible and intermediate Acinetobacter baumannii strains. J. Antimicrob. Chemother. 47, 479-482.
38. SHENG W., WANG J., LI S., LIN Y., CHENG A., CEN Y., CHANG S. (2011). Comparative in vitro antimicrobial activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU. Diagn. Microbiol. Infect. Dis. 70, 380-386.
39. SONG J.Y., CHEONG H.J., LEE J., SUNG A.K., KIM W.J. (2009). Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model. Int. J. Antimicrob. Agents. 33, 33-39.
40. SONG J.Y., KEE S.Y., HWANG I.S., SEO Y.B., JEONG H.W., KIM W.J., CHEONG H.J. (2007). In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii. J. Antimicrob. Chemother. 60, 317-322.
41. YILMAZ M. E., SUNBUL M., AKSOY A., YILMAZ H., GUNEY A.K., GUVENC T. (2012). Efficacy of tigecycline/colistin combination in a pneumonia model caused by extensively drug-resistant Acinetobacter baumannii. Int. J. Antimicrob. Agents. 40, 332-336.